tirzepatide for type 2 diabetes New research from the SURPASS-EARLY trial found that improved glycemic control, body weight, and waist circumference over 104 weeks compared with intensified conventional care in adults with early Tirzepatide for diabetes: on track

The benefit emerged early in the trial, before significant weight loss was observed

Recently, a new generation of incretin-based therapies has emerged, including dual agonists that target the GLP-1/GIP receptors (e.g., tirzepatide) or the GLP-1/glucagon receptors (e.g., cotadutide and survodutide), as well as triple agonists that act on the GLP-1, GIP, and glucagon receptors (e.g., retatrutide) (Targher et al., 2023[76], 2025[77])

Complete tablet erosion was observed regardless of water volume but occurred at a slower rate with 50 mL versus 240 mL, resulting in higher semaglutide plasma exposure with lower water volumes (Fig

While short-term side effects like nausea and gastrointestinal issues are common, long-term effects require careful monitoring and management

The Phase 3 trials extend this escalation period and allow dose flexibility based on individual tolerance

Intranasal Oxytocin Versus Placebo for Hyperphagia and Repetitive Behaviors in Children with Prader-Willi Syndrome: A Randomized Controlled Pilot Trial